Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Blogs > Disease > Movember: Prostate cancer, largely controllable, still kills; increasing...

Movember: Prostate cancer, largely controllable, still kills; increasing prevalence driving drug development

November 22, 2018 | Disease

Roxanna guilford-blake

It’s November, and if the men around you are sporting especially robust moustaches, don’t worry. It means they are paying attention to their health.
During Movember–a mashup of “moustache” and “November”–men grow out their moustaches to raise awareness of men’s health issues.

It’s not just about awareness: The Movember Foundation is a global charity focused solely on men’s health–especially suicide prevention and mental health, and testicular and prostate cancer.
We’re focusing on prostate cancer. But because it affects only men, and men are less likely to seek preventive care than women, awareness is crucial. Early diagnosis usually means a positive prognosis. But men aren’t getting that early diagnosis.

Disturbing changes

Overall cancer incidence (1999-2014) and mortality rates (1999-2015) have dropped, according to 2018 Annual Report to the Nation on the Status of Cancer. But the news isn’t as positive for prostate cancer. Researchers reported increased incidence of late-stage prostate cancer; they also found that, after decades of decline, prostate cancer mortality has stabilized. Perhaps of greatest concern is an increase in men diagnosed with late-stage prostate cancer that has spread.

Roughly 164,690 prostate cancer diagnoses will be made before the year is over, according to the American Cancer Society. More distressing, 29,430 men will die from the disease. Globally, prostate cancer diagnoses are expected to double to 1.7 million by 2030.

A January 2018 report from Datamonitor Healthcare estimates that the cases of prostate cancer will increase by more than 25 percent between the 2016 and 2036 across the US, Japan, France, Germany, Italy, Spain, and in the UK.

In the U.S., prostate cancer is the second-leading cause of cancer death in men, behind lung cancer. That’s one reason Movenber is so important: Not merely that men are dying, but that it’s largely preventable. When caught early, successful treatment and recovery is likely, with 5-year relative survival rates for localized and locally advanced disease approaching 100%. Source: SEER 2018

Current therapies

Given the number of men affected, there’s tremendous incentive for drug development. So it’s little surprise that an array of drugs are approved for prostate cancer. Among the newer ones are anti-androgen medications. By decreasing testosterone levels, they starve the cancer cells. Research has shown that anti-androgen drugs can delay cancer growth, in many cases by years.

Androgen deprivation is, of course, considered a form of chemical castration. However, castration-resistant prostate cancer (CRPC) keeps growing no matter how much the testosterone drops. Treating CRPC remains an unmet need in prostate cancer, which has spurred drug development.

New approaches, new challenges

CRPC drug development will likely change the way that the disease is treated, creating a competitive environment for new market entrants, according to the January 2018 Datamonitor report. Treatment may become more segmented as pipeline drugs with new mechanisms of action
reach the market.

However, novel therapies tend to be expensive and are likely to drive up the cost of treatment. Payers in the U.S. and France, Germany, Italy, Spain and the U.K. have expressed concern about the significant and rising cost of prostate cancer treatment, according to a June 2017 Datamonitor report.

In particular, they are worried about rising costs associated with the use of expensive novel anti-androgens in earlier treatment lines. Patients needing anti-androgens represent larger patient numbers than those with CRPC, and they also require significantly longer treatment durations due
to longer life expectancies and slower disease progression.

So, this Movember…

Development of efficacious therapies for prostate cancer treatment, particularly CRPC, remains an area of high demand. Find out more about the Prostate Cancer Market.

Related Products

Prostate Cancer Disease
Prostate Cancer Pricing Reimbursement Access

FacebookTweetPin

Related posts:

Coronavirus: A catalyst for digital health?
Disease

Coronavirus: A catalyst for digital health?

  • March, 20 2020
  • 1576

Every cloud has a silver lining. Coronavirus will be the same. One of its silver linings may be faster uptake of digital health tools and gadgets, as individuals are compelled to remain at home amid one of the century’s most concerning pandemics.   

More Options for Ovarian cancer
Disease

More Options for Ovarian cancer

  • March, 17 2020
  • 1037

One in 78 women will suffer from ovarian cancer during their lifetime. The condition accounts for more deaths than any other cancer of the reproductive system – and ranks fifth in overall cancer deaths among women.  The good news is that the range

The Big 2020 Challenge
Disease

The Big 2020 Challenge

  • January, 16 2020
  • 2152

Over the last three decades, the biotechnology industry has transformed our medicines cabinet, bringing new, effective treatments for a range of unmet needs, from rare genetic conditions, to stubborn cancers and debilitating chronic diseases. Yet several

Related Content
Read more
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
Orphan Assets Still Hot as Pricing Debate Rages In respiratory diseases, it is all about delivery

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top